NMTRQ (9 Meters Biopharma) Receivables Turnover: 0.00 (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 9 Meters Biopharma Receivables Turnover?

9 Meters Biopharma NMTRQ -99.00% Receivables Turnover is 0.00 as of Mar. 2023.

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. 9 Meters Biopharma's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. 9 Meters Biopharma's average Accounts Receivable for the three months ended in Mar. 2023 was $0.00 Mil.

9 Meters Biopharma  (OTCPK:NMTRQ) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

9 Meters Biopharma Receivables Turnover Related Terms

9 Meters Biopharma Receivables Turnover Historical Data

* Premium members only.

The historical data trend for 9 Meters Biopharma's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

9 Meters Biopharma Receivables Turnover Chart

9 Meters Biopharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

9 Meters Biopharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NMTRQ vs USRM, NOVNQ, ONCSQ: Receivables Turnover Comparison

For the Biotechnology subindustry, 9 Meters Biopharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

9 Meters Biopharma Receivables Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where 9 Meters Biopharma's Receivables Turnover falls into.


9 Meters Biopharma Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

9 Meters Biopharma's Receivables Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Receivables Turnover (A: Dec. 2022 )
=Revenue / Average Accounts Receivable
=Revenue (A: Dec. 2022 ) / ((Accounts Receivable (A: Dec. 2021 ) + Accounts Receivable (A: Dec. 2022 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

9 Meters Biopharma's Receivables Turnover for the quarter that ended in Mar. 2023 is calculated as

Receivables Turnover (Q: Mar. 2023 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Mar. 2023 ) / ((Accounts Receivable (Q: Dec. 2022 ) + Accounts Receivable (Q: Mar. 2023 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Receivables Turnover →
What does a Receivables Turnover of 0.00 mean?
9 Meters Biopharma (NMTRQ) has a Receivables Turnover of 0.00 as of Mar. 2023. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on 9 Meters Biopharma and its competitors.
Is 9 Meters Biopharma's Receivables Turnover too high?
9 Meters Biopharma's current Receivables Turnover is 0.00.
How does 9 Meters Biopharma's Receivables Turnover compare to USRM and NOVNQ?
9 Meters Biopharma's Receivables Turnover of 0.00 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on 9 Meters Biopharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 9 Meters Biopharma's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 9 Meters Biopharma stock overvalued right now?
9 Meters Biopharma (NMTRQ) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For 9 Meters Biopharma (NMTRQ), the current Receivables Turnover is 0.00 as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

9 Meters Biopharma Business Description

Address 4509 Creedmoor Road, Suite 600, Raleigh, NC, USA, 27612
9 Meters Biopharma Inc is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. Its pipeline includes vurolenatide, a proprietary Phase 3 long-acting glucagon-like-peptide 1 (GLP-1) agonist for short bowel syndrome (SBS) and a robust pipeline of early-stage candidates for undisclosed rare diseases and/or unmet needs.